# Microbial metabolites and Innate Immunity in AH: Biomarkers of injury and repair

> **NIH NIH U01** · CLEVELAND CLINIC LERNER COM-CWRU · 2020 · $249,999

## Abstract

ABSTRACT
Alcohol abuse is a leading cause of morbidity and mortality worldwide. In the US, 18 million Americans abuse
alcohol, with alcoholic liver disease (ALD) affecting over 10 million people. ALD comprises a spectrum of
disorders and pathologic changes, ranging from steatosis to alcoholic hepatitis (AH) and cirrhosis. AH is the
most severe form of ALD and can develop at any time in the progression of disease. Prednisolone, the
standard therapy for severe AH, is not effective in many patients. In steroid-resistant patients, the 6-month
mortality rate can reach 45%. Mortality in AH is primarily driven by severity of end-stage liver disease, but risk
of death in AH is also increased by multi-organ failure (MOF) in patients presenting with systemic inflammatory
response (SIRS), which occurs even in the absence of infections, elevated circulating lipopolysaccharide or
acute kidney injury (AKI). Understanding the pathophysiological mechanisms by which alcohol abuse drives
these extra-hepatic complications will lead to the identification of biomarkers to identify AH patients at high risk
for specific complications, as well new rationally-designed therapeutic targets to reduce complications. During
the first funding cycle of the ASH U01 consortia, our studies in pre-clinical murine models of AH, as well as
translational studies in patients with AH, identified key targets of alcohol action that impact the intersection
between microbial metabolism in the gut and activation of complement, a critical arm of the innate immune
system that is involved in both inflammation and wound healing. Here we propose to determine whether these
targets contribute to severity of AH, as well as complications in AH, including SIRS and AKI, that contribute to
increased mortality. These studies will focus on the development of biomarkers that are predictive of the
pathogenic progression of AH, as well as provide mechanistic insight leading to improved design of therapeutic
interventions specifically targeting disease processes and resolution of injury. Our proposed Translational
Studies are part of the Alcoholic Hepatitis Clinical and Translational Network, making use of clinical samples
and patient data from both the Late Phase Clinical Trial and Observational Study, as coordinated by the Data
Coordinating Centers. We will pursue two related, but independent, aims to develop 1) A biomarker signature
for the gut microbe metabolites TMA and TMAO that predicts severity and clinical outcomes in AH and
2) a complement activation molecular pattern (CAMPs) signature that differentiates between patients with
enhanced inflammatory responses predictive of increased severity of liver disease, incidence of SIRS/AKI and
death vs enhanced wound healing and reparative responses associated with improved survival from AH. The
development of TMA-biomarker and CAMP-biomarker signatures will have significant clinical impact by
enabling clinicians to predict the clinical course of AH and infor...

## Key facts

- **NIH application ID:** 9983540
- **Project number:** 5U01AA026938-03
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** LAURA E. NAGY
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $249,999
- **Award type:** 5
- **Project period:** 2018-09-22 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9983540

## Citation

> US National Institutes of Health, RePORTER application 9983540, Microbial metabolites and Innate Immunity in AH: Biomarkers of injury and repair (5U01AA026938-03). Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/grant/nih/9983540. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*